


## Ane cortave acetate

<b>Cat. No.:</b>	HY-116868		
<b>CAS No.:</b>	7753-60-8		
<b>Molecular Formula:</b>	C <sub>23</sub> H <sub>30</sub> O <sub>5</sub>		
<b>Molecular Weight:</b>	386.48		
<b>Target:</b>	PAI-1		
<b>Pathway:</b>	Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

<b>Description</b>	Ane cortave acetate is a potent ocular angiostatic agent. Ane cortave acetate inhibits neovascularization which is induced by many different angiogenic factors, and increases plasminogen activator inhibitor-1 (PAI-1) mRNA expression. Ane cortave acetate can be used to research ocular neovascular diseases <sup>[1][2]</sup> .																		
<b>IC<sub>50</sub> &amp; Target</b>	PAI-1 <sup>[2]</sup>																		
<b>In Vivo</b>	<p>Ane cortave acetate (5 µl of a 10% suspension; Injected into eyes) significantly inhibits pathologic retinal angiogenesis and increases PAI-1 mRNA levels<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td><b>Animal Model:</b></td> <td colspan="3">Sprague-Dawley albino rats (intravitreally injected with premixed antibiotics to influence retinal vessel growth)<sup>[2]</sup></td> </tr> <tr> <td><b>Dosage:</b></td> <td colspan="3">5 µl of a 10% suspension of Ane cortave acetate</td> </tr> <tr> <td><b>Administration:</b></td> <td colspan="3">Injected into eyes</td> </tr> <tr> <td><b>Result:</b></td> <td colspan="3">           significantly inhibited pathologic retinal angiogenesis in this model, while not significantly affecting normal intraretinal vessels.            Increased 6-to-9-fold PAI-1 mRNA at 1 to 3 days after injection.         </td> </tr> </table>			<b>Animal Model:</b>	Sprague-Dawley albino rats (intravitreally injected with premixed antibiotics to influence retinal vessel growth) <sup>[2]</sup>			<b>Dosage:</b>	5 µl of a 10% suspension of Ane cortave acetate			<b>Administration:</b>	Injected into eyes			<b>Result:</b>	significantly inhibited pathologic retinal angiogenesis in this model, while not significantly affecting normal intraretinal vessels. Increased 6-to-9-fold PAI-1 mRNA at 1 to 3 days after injection.		
<b>Animal Model:</b>	Sprague-Dawley albino rats (intravitreally injected with premixed antibiotics to influence retinal vessel growth) <sup>[2]</sup>																		
<b>Dosage:</b>	5 µl of a 10% suspension of Ane cortave acetate																		
<b>Administration:</b>	Injected into eyes																		
<b>Result:</b>	significantly inhibited pathologic retinal angiogenesis in this model, while not significantly affecting normal intraretinal vessels. Increased 6-to-9-fold PAI-1 mRNA at 1 to 3 days after injection.																		

### REFERENCES

- [1]. Clark AF. Mechanism of action of the angiostatic cortisone ane cortave acetate. *Surv Ophthalmol.* 2007 Jan;52 Suppl 1:S26-34.
- [2]. Penn JS, et al. The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. *Invest Ophthalmol Vis Sci.* 2001 Jan;42(1):283-90.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA